Methylcobalamin Deficiency Type cblE (Methionine Synthase Reductase Deficiency) — Research Report

1. Disease Information

Overview

Methylcobalamin deficiency type cblE (also called homocystinuria-megaloblastic anemia, cblE type; HMAE) is a rare autosomal recessive inborn error of intracellular cobalamin (vitamin B12) metabolism. It results from biallelic pathogenic variants in MTRR, which encodes methionine synthase reductase — an enzyme required to periodically reactivate methionine synthase (MTR/MS) by reductive methylation. Loss of MTRR function causes functional deficiency of methionine synthase despite the enzyme itself being structurally normal, producing impaired remethylation of homocysteine to methionine. The clinical result is combined homocystinuria and megaloblastic anemia, typically with hypomethioninemia, in the absence of methylmalonic aciduria (distinguishing it from the "combined" cobalamin defects such as cblC/cblD/cblF) (GeneReviews, NBK1328; OMIM #236270).

Key Identifiers

• OMIM phenotype: #236270 — Homocystinuria-Megaloblastic Anemia, cblE Type (HMAE)
• OMIM gene: *602568 — METHIONINE SYNTHASE REDUCTASE; MTRR
• MONDO: MONDO:0009354
• Orphanet: ORPHA:2169 (methionine synthase reductase deficiency); grouped clinically with cblG and cblD-variant 1 under ORPHA:622 "Homocystinuria without methylmalonic aciduria"
• MedGen: C1856057
• HGNC: 7473 (MTRR)
• UniProt: Q9UBK8 (MTRR protein, 698 amino acids, ~77.7 kDa)
• Gene location: chromosome 5p15.31 (5p15.3–15.2 in older literature); gene spans ~34 kb, 15 exons
• Inheritance: Autosomal recessive (Sources: OMIM #236270, OMIM *602568, NORD/MONDO, UniProt Q9UBK8, GeneReviews NBK1328)

Synonyms

• Methionine synthase reductase deficiency
• cblE-type homocystinuria / cblE disease
• Homocystinuria-megaloblastic anemia, cblE type (HMAE)
• Vitamin B12-responsive megaloblastic anemia due to methionine synthase reductase deficiency

Data Source Character

Nearly all available information is derived from case reports and small case series (individual patients and sibships), not large aggregated cohorts or EHR-based studies — reflecting the extreme rarity of the disease. The largest published cohort ("24 patients with the cblE or cblG remethylation defect") is a multi-center retrospective compilation (Huemer et al., J Inherit Metab Dis 2015; PMID not directly retrieved here, DOI 10.1007/s10545-014-9803-7), still a case-series design rather than population-level data.

2. Etiology

Disease Causal Factors

cblE is a purely genetic (Mendelian) disorder. Biallelic loss-of-function or hypomorphic variants in MTRR impair the reductive-methylation reactivation of methionine synthase (MTR), which uses methylcobalamin (MeCbl) as a cofactor to transfer a methyl group from 5-methyltetrahydrofolate to homocysteine, forming methionine. MTR undergoes occasional oxidative inactivation (cob(II)alamin state) during turnover; MTRR restores it to the active cob(I)alamin state using electrons from NADPH shuttled through FAD and FMN cofactors, with S-adenosylmethionine (SAM) as the methyl donor for reactivation. Without functional MTRR, MTR activity progressively declines, causing accumulation of homocysteine and depletion of methionine/SAM (WebSearch synthesis of MTRR mechanism; ScienceDirect topic pages; GeneReviews NBK1328).

Genetic Risk Factors

• Causal variants: Biallelic pathogenic MTRR variants (missense, nonsense, splice-site, small indels, and a truncating frameshift). GeneReviews reports that sequence analysis detects the majority (21 of 22 reported variant types in one series) of pathogenic alleles (GeneReviews NBK1328).
• Notable variants:
• c.1361C>T (p.Ser454Leu), sometimes reported as p.Ser545Leu in different transcript numbering — an "Iberian-origin" founder-type variant associated with a milder phenotype with no evident neurologic involvement in homozygotes (ClinVar RCV000007449; GeneReviews NBK1328; ResearchGate case report "CblE type of homocystinuria: Mild clinical phenotype... novel mutation").
• G487R (glycine-to-arginine at codon 487) — reported in homocystinuria-megaloblastic anemia patients.
• A heterozygous truncating mutation in two siblings (OMIM 602568.0001) was among the first pathogenic MTRR alleles identified.
• Additional ClinVar-curated variants include c.2073C>T (p.Arg691=, synonymous, uncertain significance in some records), c.1952+17C>A (intronic), and c.-119T>C (5′ UTR) (ClinVar RCV000907261, RCV003618859, RCV001530449).
• No common susceptibility loci or modifier genes have been robustly established for cblE specifically, though the common MTRR polymorphism A66G (p.Ile22Met) has been studied extensively in the general population as a modifier of folate/homocysteine status and disease risk (neural tube defects, cardiovascular disease) — this is distinct from the rare biallelic pathogenic variants causing cblE disease itself.

Environmental Risk Factors

• Maternal/dietary vitamin B12 or folate status: While cblE is a primary genetic enzyme defect (not a nutritional deficiency), functional cobalamin/folate status can modulate phenotypic severity, since MTRR partially rescues residual methionine synthase activity when cobalamin is abundant — this underlies the rationale for high-dose parenteral hydroxocobalamin therapy.
• No infectious, occupational, or toxic environmental triggers have been described as causal for cblE; it is a monogenic disease that is fully penetrant when biallelic pathogenic variants are present, though age of onset and severity vary (GeneReviews NBK1328).

Protective Factors

• No specific protective genetic variants against cblE disease itself have been reported (as opposed to studies of the common MTRR A66G polymorphism in other multifactorial contexts).
• Vitamin B12 (hydroxocobalamin) responsiveness functions as a therapeutic/mitigating factor rather than a true "protective factor," since residual enzyme activity in hypomorphic alleles can be augmented pharmacologically.

Gene-Environment Interactions

• The core gene-environment interaction in cblE pathophysiology is the substrate-driven rescue mechanism: supraphysiologic (pharmacologic) doses of hydroxocobalamin increase intracellular cobalamin pools sufficiently to partially bypass the reductive-reactivation defect in some hypomorphic MTRR variants, explaining "cobalamin responsiveness" as a treatment principle (GeneReviews NBK1328; multiple case reports).
• Maternal folate/B12 status during pregnancy is relevant to the broader MTRR biology (e.g., mouse models — see Section 15) but is not established as a modifier of cblE disease severity in affected humans specifically.

3. Phenotypes

cblE produces a relatively narrow, well-defined phenotypic triad: megaloblastic anemia, neurologic/developmental impairment, and biochemical homocystinuria with hypomethioninemia — but with documented phenotypic heterogeneity in severity and organ involvement.

Hematologic

• Megaloblastic anemia (macrocytic anemia with megaloblastic bone marrow changes) — the most consistent and often presenting feature. Reported as isolated in some patients.
• HP suggestion: HP:0001889 (Megaloblastic anemia)
• Pancytopenia / early-onset bone marrow failure has been reported, sometimes remaining isolated without neurologic involvement (WebSearch synthesis, PMC article on late-onset hemolytic anemia complication).
• HP suggestion: HP:0001876 (Pancytopenia)
• Late-onset refractory hemolytic anemia as a rare treatment-related/disease complication in siblings on long-term therapy, potentially preventable by hydroxocobalamin dose escalation (PMC11078714, "Late-onset refractory hemolytic anemia in siblings treated for methionine synthase reductase deficiency").
• HP suggestion: HP:0001878 (Hemolytic anemia)

Neurologic / Developmental

• Developmental delay / delayed psychomotor development, frequently reported (HP:0002194)
• Intellectual disability / cognitive dysfunction (HP:0001249)
• Hypotonia (HP:0001252)
• Seizures, described as "frequent" in some series (HP:0001250)
• Cerebral atrophy on neuroimaging (HP:0002059)
• Lethargy (HP:0001254)

Ophthalmologic

• Nystagmus (HP:0000639)
• Impaired visual acuity without lens dislocation — notably distinguishing cblE from classic CBS-deficiency homocystinuria, which characteristically causes ectopia lentis (HP:0000572, visual impairment)
• Macular dysfunction, described as a rare feature (relevant HP term e.g. HP:0007754 macular dystrophy, if applicable per specific case)

Growth / Constitutional

• Failure to thrive / feeding difficulties, often an early presenting sign (HP:0001508 / HP:0011968)
• Severe growth failure — GeneReviews specifically states "most children with cblE present in the first two years of life with severe growth failure, megaloblastic anemia, and neurologic manifestations" (GeneReviews NBK1328)

Renal

• Hemolytic uremic syndrome (HUS) — described as occurring in a subset of patients ("isolated megaloblastic anemia and HUS may also be seen")
• HP suggestion: HP:0005575 (Hemolytic-uremic syndrome)
• Atypical glomerulopathy — described in an adolescent-onset presentation (GeneReviews NBK1328)

Laboratory Abnormalities (biochemical phenotypes, distinct from clinical signs)

• Elevated total plasma homocysteine (hyperhomocysteinemia) and homocystinuria (elevated urinary homocystine)
• Low-to-normal plasma methionine (hypomethioninemia) and low S-adenosylmethionine (SAM)
• Normal urine/plasma methylmalonic acid (MMA) — key distinguishing feature from combined (cblC/D/F) and isolated methylmalonic-acidemia cobalamin defects
• No elevated propionylcarnitine (C3) on newborn screening acylcarnitine profile, which is why cblE and cblG are typically missed by standard newborn screening (GeneReviews NBK1328)

Phenotype Characteristics

• Age of onset: Most commonly between 2 weeks and 3 years of age; GeneReviews specifies presentation "in the first two years of life" for the classic severe form; rarer adolescent-onset presentation with atypical glomerulopathy has also been described (GeneReviews NBK1328; multiple case-report sources).
• Severity: Highly variable — from mild phenotype with isolated megaloblastic anemia and no neurologic involvement (e.g., homozygous c.1361C>T/p.Ser454Leu patients) to severe early-onset multisystem disease with profound developmental delay, seizures, and growth failure.
• Progression: Generally chronic and, if untreated, progressive; treatment with parenteral hydroxocobalamin and betaine can stabilize biochemical parameters, but neurodevelopmental and ophthalmologic outcomes are only partially responsive.
• Frequency among affected individuals: Formal frequency percentages for individual phenotypes are not well established given the very small published patient numbers (fewer than 40 cumulative cblE + cblG cases reported per GeneReviews).

Quality of Life Impact

No disease-specific quality-of-life instrument data were identified in the literature searched. Neurodevelopmental impairment (intellectual disability, seizures) and visual impairment are the primary drivers of long-term functional impact; the JIMD cohort study (Huemer et al. 2015) explicitly notes that "the overall impact of treatment on neurodevelopmental disabilities and eye disease was at most moderate," implying persistent long-term QoL burden even with treatment (WebSearch synthesis of JIMD 2015 paper).

4. Genetic / Molecular Information

Causal Gene

• MTRR (5-methyltetrahydrofolate-homocysteine methyltransferase reductase), HGNC:7473, chromosome 5p15.31, ~34 kb genomic span, 15 exons.
• OMIM gene entry: *602568.

Protein / Function

• MTRR is a diflavin oxidoreductase of the ferredoxin-NADP+ reductase family, structurally related to cytochrome P450 reductase and nitric oxide synthase reductase domains.
• Domain architecture: N-terminal FMN-binding domain (flavodoxin-like) + C-terminal FAD/NADPH-binding domain (ferredoxin-NADP+ reductase-like).
• Mechanism: Acquires electrons from NADPH, passes them sequentially through FAD → FMN, then to cob(II)alamin bound to methionine synthase (MTR), reducing it to cob(I)alamin, which is then remethylated by S-adenosylmethionine (SAM) to regenerate active methylcobalamin-bound MTR.
• MTRR forms part of a multiprotein complex with MMACHC, MMADHC (the cblC/cblD gene products) and MTR itself, integrating it into the broader intracellular cobalamin-processing pathway.
• (Sources: WebSearch synthesis of GeneCards/UniProt/PNAS cloning paper; ScienceDirect topic overview)

Pathogenic Variants

• Gene: MTRR (HGNC:7473)
• Variant classification: Reported alleles span pathogenic and likely pathogenic per ACMG/AMP in ClinVar; variant of uncertain significance for some synonymous/intronic changes (e.g., c.2073C>T p.Arg691=).
• Variant types: Missense (majority; e.g., p.Ser454Leu/p.Ser545Leu, G487R), nonsense/truncating (e.g., the original heterozygous truncating mutation OMIM 602568.0001), splice-region (c.1952+17C>A), and regulatory/5′UTR (c.-119T>C).
• Allele frequency: No large population allele-frequency data specific to disease-causing MTRR variants were retrieved; the disorder is exceedingly rare (fewer than 40 cumulative cblE+cblG cases reported), consistent with very low allele frequencies in gnomAD for the pathogenic alleles (not independently queried in this session).
• Origin: Germline, autosomal recessive (biallelic).
• Functional consequences: Loss-of-function or hypomorphic reduction of MTRR reductase activity → impaired reactivation of methionine synthase → functional methionine synthase deficiency despite normal MTR protein.
• Genotype-phenotype correlation: The c.1361C>T (p.Ser454Leu) variant, described as of Iberian origin, is specifically associated with a milder phenotype without neurologic involvement in homozygotes — one of the few reasonably well-documented genotype-phenotype correlations in this disease (GeneReviews NBK1328; case report literature).

Modifier Genes

No confirmed modifier genes for cblE disease severity were identified in the literature retrieved. The common MTRR A66G (p.Ile22Met) polymorphism is studied as a population-level modifier of homocysteine/folate metabolism in unrelated contexts (e.g., neural tube defect risk, Down syndrome risk in some association studies) but is not established as a modifier of cblE disease phenotype in affected individuals.

Epigenetic Information

No disease-specific epigenetic (DNA methylation, histone modification) studies in human cblE patients were identified. However, mouse Mtrr hypomorphic models show that MTRR/folate-methionine pathway disruption causes DNA methylation dysregulation transgenerationally (see Section 15), suggesting a plausible but human-unconfirmed epigenetic dimension to pathophysiology, since SAM (whose production is impaired in cblE) is the universal methyl donor for DNA/histone methylation.

Chromosomal Abnormalities

No chromosomal-scale abnormalities (aneuploidy, translocations) are described as causal for cblE; it is a single-gene, point-mutation/small-indel disorder.

5. Environmental Information

• Environmental factors: None established as independently causal; cblE is monogenic. However, functional cobalamin sufficiency (dietary/parenteral) modulates phenotype expression pharmacologically.
• Lifestyle factors: Not applicable as causal factors; dietary protein restriction is specifically not recommended as part of management (see Section 12), distinguishing cblE from disorders like classic homocystinuria or organic acidemias where dietary protein restriction is standard.
• Infectious agents: None implicated.

6. Mechanism / Pathophysiology

Causal Chain

1. Molecular trigger: Biallelic pathogenic MTRR variants → reduced/absent methionine synthase reductase activity.
2. Enzymatic consequence: Methionine synthase (MTR/MS), which cycles between active cob(I)alamin-bound and inactive cob(II)alamin-bound states during normal catalysis (~1 in 2,000 turnovers undergoes oxidative inactivation), cannot be efficiently reactivated by reductive methylation. MTR activity progressively declines despite the MTR protein itself and its bound cobalamin cofactor being intact.
3. Biochemical consequence: Impaired remethylation of homocysteine → methionine via the 5-methyltetrahydrofolate-homocysteine methyltransferase reaction. This causes:
4. Homocysteine accumulation (hyperhomocysteinemia/homocystinuria)
5. Methionine and SAM depletion (hypomethioninemia)
6. Folate trapping: as 5-methyltetrahydrofolate cannot be demethylated (the "methylfolate trap"), cellular folate becomes sequestered in a form unusable for purine/thymidylate synthesis.
7. Cellular consequence: Impaired thymidylate synthesis (via depleted folate cofactors needed for the thymidylate synthase cycle) → impaired DNA synthesis in rapidly dividing cells, especially hematopoietic precursors → megaloblastic changes and ineffective erythropoiesis (megaloblastic anemia).
8. Systemic/organismal consequence: SAM depletion impairs global transmethylation reactions (including neuronal myelin and neurotransmitter methylation pathways), contributing to neurodevelopmental impairment, hypotonia, and seizures. Elevated homocysteine itself is thought to contribute to vascular/endothelial and possibly neurologic toxicity, analogous to (but generally milder than) classic CBS-deficiency homocystinuria vasculopathy — although lens dislocation, a hallmark of CBS deficiency, is characteristically absent in cblE, suggesting distinct mechanisms of connective-tissue involvement (or its absence) between the disorders.

Upstream vs. Downstream

• Upstream: MTRR loss-of-function (molecular/enzymatic).
• Midstream: Functional methionine synthase deficiency; homocysteine/SAM/folate cycle disruption (cellular/metabolic).
• Downstream: Megaloblastic hematopoiesis (cellular/tissue), CNS dysmyelination/developmental impairment (tissue/organism), possible renal microangiopathy/HUS (organism).

Cell Types and Biological Processes Involved

• Hematopoietic precursor cells (erythroid lineage) — impaired DNA synthesis, megaloblastic change.
• CL suggestion: CL:0000765 (erythroblast) or CL:0000038 (erythroid progenitor cell)
• Neurons / glial cells — impaired methylation-dependent myelination and neurotransmitter metabolism.
• CL suggestion: CL:0000540 (neuron)
• Renal glomerular/endothelial cells — implicated in the rare HUS/atypical glomerulopathy phenotype, potentially via homocysteine-mediated endothelial injury (analogous to mechanisms proposed in cblC-associated HUS).
• CL suggestion: CL:0002138 (endothelial cell of vascular tree) or CL:1001005 (glomerular visceral epithelial cell)

Molecular Pathways / GO Terms

• One-carbon metabolism / folate cycle (KEGG: hsa00670 One carbon pool by folate; hsa00270 Cysteine and methionine metabolism)
• GO Biological Process suggestions:
• GO:0033353 (S-adenosylmethionine cycle)
• GO:0009086 (methionine biosynthetic process)
• GO:0050667 (homocysteine metabolic process)
• GO:0032259 (methylation)
• GO Molecular Function suggestions:
• GO:0030350 (iron-responsive element binding — not relevant; correct term:)
• GO:0050660 (flavin adenine dinucleotide binding)
• GO:0010181 (FMN binding)
• GO:0004489 (methylenetetrahydrofolate reductase [NAD(P)H] activity — for MTHFR, not MTRR; for MTRR specifically:)
• GO:0016860 (intramolecular oxidoreductase activity) — verify against current GO for "methionine synthase reductase activity" annotation, e.g., GO:0030744 (methionine synthase reductase activity, if extant) — flag for verification with OAK/GO adapter before binding in KB entry.
• GO Cellular Component: GO:0005829 (cytosol) — MTRR is a cytosolic enzyme.

Biochemical Abnormalities

• Enzyme deficiency: methionine synthase reductase (EC 1.16.1.8) activity loss.
• Functional/secondary enzyme deficiency: methionine synthase (EC 2.1.1.13) activity decreased under standard fibroblast assay conditions with suboptimal reducing agent — this is the key enzymatic distinguishing test between cblE and cblG: in cblE, MTR activity is preserved with excess exogenous reducing agent but falls under limiting conditions; in cblG, MTR activity is decreased under all conditions because the MTR apoenzyme itself is defective (WebSearch synthesis of Watkins 1989, AJMG; ScienceDirect topic page).

Immune System Involvement

No primary immune dysfunction is characteristic of cblE; it is not classified as a primary immunodeficiency.

Tissue Damage Mechanisms

Ineffective erythropoiesis (megaloblastic anemia) and possible endothelial/microvascular injury contributing to the rare HUS/glomerulopathy phenotype are the principal described tissue-damage mechanisms; direct evidence for oxidative-stress or fibrotic mechanisms specific to cblE was not identified in the literature retrieved.

Molecular Profiling / Advanced Technologies

No transcriptomic, proteomic, metabolomic, single-cell, or spatial-omics studies specific to human cblE patient tissue were identified in this search. Metabolomic characterization is largely limited to targeted amino acid/homocysteine/methylmalonic acid panels used diagnostically (see Section 10), not unbiased -omics profiling.

7. Anatomical Structures Affected

Organ Level

• Primary: Bone marrow (hematopoietic system) — megaloblastic anemia/pancytopenia; Central nervous system — developmental delay, seizures, hypotonia, cerebral atrophy.
• Secondary: Eye (nystagmus, visual impairment, rare macular dysfunction); Kidney (rare HUS, atypical glomerulopathy).
• Body systems involved: Hematologic, nervous, ophthalmologic, and (rarely) renal systems.

UBERON suggestions: UBERON:0002371 (bone marrow), UBERON:0000955 (brain), UBERON:0000970 (eye), UBERON:0002113 (kidney).

Tissue and Cell Level

• Erythroid precursor cells in bone marrow (megaloblastic changes)
• Neural tissue — white matter/myelin-relevant cell populations
• Renal glomerular capillary endothelium (in HUS/glomerulopathy presentations)

Subcellular Level

• Cytosol: MTRR and MTR are cytosolic enzymes; the folate/methionine cycle operates in the cytosolic compartment.
• GO Cellular Component: GO:0005829 (cytosol)

Localization

No specific lateralization pattern is described; CNS and hematologic involvement are systemic/bilateral by nature.

8. Temporal Development

Onset

• Typical age: 2 weeks to 3 years of age (most common); classic presentation "in the first two years of life."
• Rare atypical: Adolescent-onset presentation with atypical glomerulopathy has been described.
• Onset pattern: Generally insidious/subacute, evolving over weeks to months in infancy, though acute presentations (e.g., with HUS) can occur.

Progression

• Disease course pattern: Chronic, generally progressive if untreated; biochemically responsive (to varying degrees) to hydroxocobalamin/betaine therapy.
• Progression rate: Variable — mild genotypes (e.g., p.Ser454Leu homozygotes) show slow/non-progressive isolated hematologic disease; severe genotypes show more rapid multisystem progression in infancy.
• Disease duration: Chronic, lifelong (enzyme deficiency is permanent; management is lifelong).

Patterns

• Remission: Biochemical parameters (homocysteine, methionine) can normalize or substantially improve with treatment; hematologic remission of megaloblastic anemia is generally achievable. Neurodevelopmental and ophthalmologic manifestations show only partial/moderate treatment response per the largest published cohort (JIMD 2015 paper).
• Critical periods: Early infancy is considered a critical window for treatment initiation to minimize neurodevelopmental sequelae, though the evidence for this is characterized in the literature as "weak" ("only weak evidence for a response to treatment and for the specific value of early treatment in cblE defects" — WebSearch synthesis of JIMD 2015 cohort paper).

9. Inheritance and Population

Epidemiology

• Prevalence/Incidence: No formal population-based incidence or prevalence rate has been established. The disease is characterized as ultra-rare, with GeneReviews stating "fewer than 40 cases have been described for cblE and cblG" combined, as of the most recent update reviewed. No newborn-screening-based incidence estimate exists because cblE (like cblG) is not reliably detected by standard newborn screening acylcarnitine profiles (no elevated propionylcarnitine/C3) (GeneReviews NBK1328).

Inheritance Pattern

• Autosomal recessive. Per GeneReviews genetic counseling section: "At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier." Parents of an affected child are obligate heterozygous carriers (GeneReviews NBK1328).
• Penetrance: Presumed complete for biallelic clearly pathogenic (loss-of-function) variants, though phenotypic severity is variable (variable expressivity), and hypomorphic alleles (e.g., p.Ser454Leu) produce milder, incompletely penetrant neurologic phenotypes.
• Carrier detection: GeneReviews notes biochemical testing is not reliable for carrier detection; molecular (sequence-based) testing with a known familial variant is required.
• Founder effects: The c.1361C>T (p.Ser454Leu) variant is specifically noted as being of Iberian origin, suggestive of a founder allele in that population.
• Consanguinity: Not specifically quantified in the sources retrieved, but as an ultra-rare autosomal recessive disorder, consanguinity would be expected to increase local incidence in affected families/populations, as is typical for such disorders.
• Carrier frequency: Not established in population databases for this session's search.

Population Demographics

• No specific ethnic/geographic prevalence data beyond the Iberian-origin founder variant were identified.
• Sex ratio: No sex predilection is described; autosomal recessive inheritance predicts equal male:female distribution.
• Age distribution: Predominantly diagnosed in infancy/early childhood, consistent with typical age of onset.

10. Diagnostics

Clinical/Laboratory Tests

• Complete blood count with peripheral smear: macrocytic/megaloblastic red cell morphology, possible pancytopenia.
• Plasma total homocysteine (tHcy): elevated.
• Urine homocystine: elevated (homocystinuria).
• Plasma amino acid panel: low-to-normal methionine (hypomethioninemia); low SAM.
• Urine and plasma methylmalonic acid (MMA): normal — key discriminating test versus combined cobalamin defects (cblC/D/F) and isolated methylmalonic acidemia disorders.
• Newborn screening acylcarnitine profile: propionylcarnitine (C3) not elevated — explains why cblE/cblG are missed on standard NBS.

LOINC/SNOMED suggestions: standard plasma amino acid and homocysteine assay LOINC codes (specific codes not independently verified in this session).

Biomarkers

• Elevated total homocysteine and low methionine/SAM ratio are the principal biochemical biomarkers.

Genetic Testing

• Molecular confirmation: Identification of biallelic pathogenic MTRR variants by sequence analysis (detects the great majority of reported pathogenic alleles per GeneReviews — "21/22 reported variants" detectable by sequencing).
• Approach: Given clinical/biochemical overlap between cblE and cblG (methionine synthase, MTR, deficiency) — "the clinical and biochemical features are virtually identical for both defects" — molecular testing (targeted gene sequencing or a remethylation-disorder gene panel including MTRR, MTR, MMACHC, MMADHC, MTHFR) is necessary to distinguish them, since biochemical testing alone cannot reliably differentiate cblE from cblG (WebSearch synthesis of Watkins 1989 AJMG paper; GeneReviews NBK1328).
• Fibroblast complementation/enzyme studies: Historically used to assign the cblE complementation group — methionine synthase activity in cultured fibroblasts is preserved with excess exogenous reducing agent but falls under limiting reducing-agent conditions in cblE (vs. uniformly decreased in cblG), enabling functional discrimination prior to/alongside molecular testing.

Clinical Criteria / Differential Diagnosis

Per GeneReviews, cblE must be distinguished from: - Vitamin B12 deficiency (nutritional) — normalizes with B12 replacement; distinguished by dietary history, low serum B12, and absence of a genetic cause. - MTHFR deficiency — produces moderate homocystinuria with normal-to-low methionine but lacks megaloblastic anemia (a key distinguishing clinical feature, since MTHFR deficiency does not impair folate-independent hematopoiesis in the same way). - CBS (cystathionine beta-synthase) deficiency (classic homocystinuria) — elevated methionine together with elevated homocysteine (vs. low methionine in cblE); classically features ectopia lentis, marfanoid habitus, and thromboembolism, generally absent in cblE. - cblG (methionine synthase/MTR deficiency) — clinically and biochemically nearly indistinguishable; requires molecular/enzymatic complementation testing to differentiate. - cblC, cblD, cblF (combined remethylation + methylmalonic acidemia defects) — distinguished by presence of elevated methylmalonic acid, which is absent in cblE.

Screening

• Not part of standard newborn screening panels due to lack of a distinguishing acylcarnitine signature; GeneReviews notes screening could theoretically be achieved by measuring methionine and the methionine-to-phenylalanine ratio in dried blood spots, with total homocysteine as a second-tier marker, but this is not currently standard practice (WebSearch synthesis).

11. Outcome / Prognosis

• Survival/mortality: No specific mortality rate statistics were retrieved; the disorder is not classically described as acutely lethal when treated, though severe untreated cases with profound neurologic and hematologic compromise in infancy could carry significant morbidity/mortality risk (not independently quantified in sources retrieved).
• Morbidity: Intellectual disability, seizures, and visual impairment represent the chief chronic morbidities. The JIMD 2015 cohort paper (24 patients) reports that even with treatment, neurodevelopmental and ophthalmologic outcomes show only "moderate" improvement at best, and that evidence for early-treatment benefit is "weak" — indicating that, unlike some other treatable inborn errors, cblE carries a persistent morbidity burden even under current standard-of-care management.
• Positive outcome signal: A smaller subset (4 patients in one cited series) showed a clearer positive impact of early treatment on outcome, suggesting genotype- or presentation-dependent prognosis heterogeneity.
• Complications: Late-onset refractory hemolytic anemia has been documented as a rare, potentially treatment-related long-term complication in siblings on chronic hydroxocobalamin/betaine therapy, possibly preventable by hydroxocobalamin dose escalation (PMC11078714).
• Prognostic factors: Genotype (e.g., p.Ser454Leu associated with milder, non-neurologic phenotype); age/timing of treatment initiation; presence/absence of early neurologic involvement at diagnosis.

12. Treatment

Pharmacotherapy

• Parenteral hydroxocobalamin (OHCbl) — the cornerstone of treatment. GeneReviews specifically emphasizes that only the parenteral hydroxocobalamin form is effective — cyanocobalamin and oral preparations are not adequate substitutes ("parenteral OHCbl (not the cyanocobalamin form or oral form) is the only effective preparation").
• NCIT suggestion: NCIT:C15986 (Pharmacotherapy) as treatment_term, with therapeutic_agent bound to a CHEBI/NCIT term for hydroxocobalamin (CHEBI:20363, hydroxocobalamin, is a plausible CHEBI ID — verify against OAK before curation).
• Betaine — supplementation (starting dose approximately 250 mg/kg/day cited in GeneReviews) to promote the alternative (cobalamin-independent) remethylation pathway via betaine-homocysteine methyltransferase (BHMT), lowering homocysteine and raising methionine.
• CHEBI suggestion: CHEBI:17750 (betaine)
• Folate/folinic acid supplementation — may be used adjunctively to support remethylation capacity.

Dietary Management

• Normal dietary protein intake is appropriate; GeneReviews explicitly states that "low-protein diets and medical foods... are not recommended" — an important distinction from CBS-deficiency homocystinuria management, which often does involve protein/methionine restriction.

Surgical / Interventional

No surgical interventions are characteristic of cblE management.

Supportive / Rehabilitative

• Developmental/early intervention services, physical/occupational therapy as indicated by neurodevelopmental impairment.
• Ophthalmologic monitoring and supportive management of visual impairment.
• Hematologic monitoring; transfusion support if severe anemia, though this is not typically the primary therapeutic modality given B12/betaine responsiveness.

Advanced Therapeutics / Experimental

• No gene therapy, cell therapy, or RNA-based therapeutics specific to cblE were identified in the literature retrieved. "Functional correction by minigene expression" has been demonstrated as a research/proof-of-concept tool (Zavadáková et al. 2005, Human Mutation, PMID referenced in search results) to characterize variant pathogenicity in cultured cells, not as a clinical therapeutic.

Treatment Outcomes

• Biochemical response (normalization/improvement of homocysteine, methionine, and hematologic parameters) is generally favorable with hydroxocobalamin + betaine.
• Neurodevelopmental and ophthalmologic response to treatment is only moderate at best, per the largest published cohort, and evidence supporting early-treatment benefit specifically is characterized as weak.
• Adverse events: Rare late-onset refractory hemolytic anemia has been documented as a treatment-era complication, discussed as potentially related to therapy dosing (PMC11078714).

Treatment Strategy

• Lifelong parenteral hydroxocobalamin plus oral betaine is the standard combination approach; no formal published treatment algorithm/consensus guideline analogous to NCCN-style pathways was identified — management is guided by case-series experience and metabolic-disease expert consensus (e.g., within the broader "Disorders of Intracellular Cobalamin Metabolism" GeneReviews chapter, which covers cblE alongside cblA, cblB, cblC, cblD, cblF, and cblG under a shared general management framework).

13. Prevention

• Primary prevention: Not applicable in the traditional sense (not preventable by lifestyle/vaccination), as cblE is a genetic disorder; the only "primary prevention" avenue is reproductive genetic counseling and prenatal/preimplantation genetic testing in families with a known pathogenic variant.
• Secondary prevention / early detection: Because standard newborn screening does not reliably detect cblE, secondary prevention currently depends on clinical suspicion in infants presenting with unexplained megaloblastic anemia and/or developmental delay, prompting targeted biochemical (homocysteine/methionine) and molecular testing. Prenatal diagnosis has been performed in at-risk families with a known familial MTRR variant (referenced in the 2001 JIMD paper "CblE type of homocystinuria due to methionine synthase reductase deficiency: Clinical and molecular studies and prenatal diagnosis in two families").
• Genetic counseling: Central to prevention in this autosomal recessive disorder — informing carrier parents of 25% recurrence risk per pregnancy, and offering carrier testing to at-risk relatives (with molecular, not biochemical, methods) and prenatal diagnosis in subsequent pregnancies.
• Screening programs: A proposed but not widely implemented dried-blood-spot approach (methionine level / methionine-to-phenylalanine ratio, with second-tier homocysteine) could theoretically enable population newborn screening for cblE, per systematic-review literature on NBS for homocystinurias and methylation disorders (Huemer et al., PMID 25762406, cited in search results), but this is not current standard practice.
• Prophylaxis: No prophylactic pharmacologic regimen (e.g., preemptive cobalamin supplementation in unaffected at-risk newborns pending testing) was described in the sources retrieved as a standardized practice, though early empiric treatment while confirmatory testing is pending is a reasonable clinical approach given the biochemical responsiveness of the disorder.

14. Other Species / Natural Disease

No naturally occurring veterinary or wildlife cases of MTRR-deficiency disease analogous to human cblE were identified in the literature searched (e.g., no OMIA entries were retrieved). The available animal data are exclusively engineered mouse models (below) rather than spontaneous natural disease in other species.

15. Model Organisms

Mouse Models (Mtrr)

The Mtrr gene-trap hypomorphic mouse model (Mtrr^gt) is the principal model system used to study MTRR/methionine-synthase-reductase pathway biology, though it models the broader folate/methionine metabolic consequences of MTRR deficiency rather than being validated specifically as a full recapitulation of the human cblE clinical syndrome (megaloblastic anemia + neurodevelopmental disease).

• Reproductive/developmental phenotypes: "Methionine synthase reductase deficiency results in adverse reproductive outcomes and congenital heart defects in mice" (Padmanabhan et al., PMID 18413293; PMC3110750). Mtrr deficiency produces hyperhomocysteinemia, dysregulated DNA methylation, and developmental phenotypes including neural tube defects, congenital heart defects, and placental defects.
• Transgenerational effects: Notably, Mtrr-deficient mice show two distinct, separable phenotypes across generations: (1) adverse uterine-environment effects transmitted to wild-type daughters causing growth defects in wild-type grandprogeny, and (2) congenital malformations that persist independent of maternal environment for 5 generations — an unusual transgenerational epigenetic inheritance phenomenon (WebSearch synthesis of PMC/related papers).
• Liver phenotype: "Mtrr hypomorphic mutation alters liver morphology, metabolism and fuel storage in mice" (PMID 32257815; PMC7109458) — Mtrr^gt/gt female mouse livers were enlarged, with eosinophilic hepatocytes and decreased glycogen content, associated with downregulation of glycogen synthesis genes.
• Reproductive/fertility phenotype in males: "Analysis of spermatogenesis and fertility in adult mice with a hypomorphic mutation in the Mtrr gene" (PMC7116358) — Mtrr^gt/gt adult testes were more spherical in shape than wild-type, but serum testosterone was normal, spermatogenesis proceeded typically, and sperm morphology/count/viability/fertility were normal — indicating preserved male fertility despite altered testicular gross morphology, i.e., a phenotype that does not fully recapitulate a severe reproductive deficit.
• Metabolic derangement: "Metabolic derangement of methionine and folate metabolism in mice deficient in methionine synthase reductase" (PMC1973089) documents the core one-carbon-metabolism biochemical perturbations (elevated homocysteine, altered folate distribution) in this model, directly relevant to the biochemical phenotype of human cblE.

Model Limitations

The mouse Mtrr models are hypomorphic (gene-trap) rather than null, and the literature retrieved emphasizes developmental, reproductive, hepatic, and epigenetic-inheritance phenotypes rather than a hematologic (megaloblastic anemia) or neurologic phenotype directly paralleling the human cblE presentation. This represents a potential human-model translational gap: the mouse literature is dominated by reproductive/developmental and transgenerational-epigenetic findings, while the human disease is characterized primarily by megaloblastic anemia and neurodevelopmental impairment — suggesting the existing Mtrr mouse models may have uncertain fidelity for the core clinical hematologic/neurologic phenotype of human cblE disease, an important consideration for any HUMAN_MODEL_MISMATCH-type annotation if this disease is curated into a mechanistic knowledge base.

Resources

• MGI: Mtrr, MGI:1891037 (Mouse Genome Informatics)
• No zebrafish (ZFIN), Drosophila (FlyBase), C. elegans (WormBase), or yeast (SGD) MTRR-ortholog disease models were identified in this search.

Summary of Key Ontology Term Suggestions for KB Curation

(All ontology term suggestions should be independently verified via OAK/just validate-terms against current canonical labels before use in a curated KB entry, per standard practice — several GO term suggestions above in Section 6 are flagged as needing verification.)

Sources

• OMIM #236270 — Homocystinuria-Megaloblastic Anemia, cblE Type
• OMIM *602568 — Methionine Synthase Reductase; MTRR
• GeneReviews — Disorders of Intracellular Cobalamin Metabolism (NBK1328)
• NORD/MONDO — Methylcobalamin deficiency type cblE
• Orphanet — Homocystinuria without methylmalonic aciduria
• ClinVar — MTRR c.1361C>T (p.Ser454Leu)
• ClinVar — MTRR c.2073C>T
• ClinVar — MTRR c.1952+17C>A
• ClinVar — MTRR c.-119T>C
• MedGen — C1856057
• Late-onset refractory hemolytic anemia in siblings treated for methionine synthase reductase deficiency (PMC11078714)
• Methionine synthase reductase deficiency (CblE): A report of two patients and a novel mutation
• Clinical onset and course... 24 patients with the cblE or cblG remethylation defect (J Inherit Metab Dis, 2015)
• Functional methionine synthase deficiency (cblE and cblG): clinical and biochemical heterogeneity (PMID 2688421)
• cblE Type of homocystinuria due to methionine synthase reductase deficiency: Functional correction by minigene expression (PMID 15714522)
• CblE type of homocystinuria due to methionine synthase reductase deficiency: Clinical and molecular studies and prenatal diagnosis in two families
• CblE type of homocystinuria: Mild clinical phenotype in two patients homozygous for a novel mutation in the MTRR gene
• Newborn screening for homocystinurias and methylation disorders: systematic review and proposed guidelines (PMID 25762406)
• Methionine synthase reductase deficiency results in adverse reproductive outcomes and congenital heart defects in mice (PMID 18413293 / PMC3110750)
• Mtrr hypomorphic mutation alters liver morphology, metabolism and fuel storage in mice (PMID 32257815 / PMC7109458)
• Analysis of spermatogenesis and fertility in adult mice with a hypomorphic mutation in the Mtrr gene (PMC7116358)
• Metabolic derangement of methionine and folate metabolism in mice deficient in methionine synthase reductase (PMC1973089)
• Cloning and mapping of a cDNA for methionine synthase reductase, a flavoprotein defective in patients with homocystinuria (PNAS 1998)
• UniProt Q9UBK8 — Methionine synthase reductase
• MGI:1891037 — Mtrr

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.